Molecular Sensors for Imaging Histone Methylations in Living Animals

用于活体动物组蛋白甲基化成像的分子传感器

• 批准号: 8245609
• 负责人: Ramasamy Paulmurugan
• 金额: $ 32.62万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8245609
• 关键词: Alanine; Animals; Azacitidine; Behavior; Binding; Biological Assay; Bioluminescence; Cell Culture Techniques; Cell Line; Cells; DNA Methylation; DNA Sequence; Development; Disease; Drug Delivery Systems; Drug Evaluation; Drug Kinetics; Drug usage; Epigenetic Process; Event; Firefly Luciferases; Functional disorder; Gene Expression; Goals; Grant; Histone Acetylation; Histones; Image; Lead; Leucine; Life; Link; Luciferases; Lysine; Malignant Neoplasms; Mammalian Cell; Measures; Methylation; Methyltransferase; Modification; Molecular; Monitor; Mus; N-terminal; Neoplasm Metastasis; Optics; Peptides; Pharmaceutical Preparations; Pharmacodynamics; Phenotype; Positron-Emission Tomography; Preclinical Drug Evaluation; Process; Protein Fragment; Proteins; Renilla; Reporter; Research; Research Proposals; Role; Specificity; System; Techniques; Testing; Therapeutic; Therapeutic Studies; Thymidine Kinase; Tretinoin; Trichostatin A; Tryptophan; Valproic Acid; Vorinostat; Work; analytical tool; base; cellular imaging; clinical application; combinatorial; drug development; flexibility; histone methyltransferase; imaging modality; improved; in vivo; inhibitor/antagonist; innovation; interest; molecular imaging; mutant; novel; novel strategies; optical imaging; pre-clinical; protein H(3); research clinical testing; response; sensor; small molecule; subcutaneous; tool; tumor xenograft

DESCRIPTION (provided by applicant): "Epigenetics" refers to changes in phenotype or gene expression caused by mechanisms other than changes in the underlying DNA sequence. Abnormal epigenetic control mechanisms are now regarded as significant contributing factors to the pathophysiology of different diseases, including cancer. The main epigenetic mechanisms that induce phenotypic changes in mammalian cells are DNA methylation, histone methylation and histone acetylation. Many recent targeted drug development efforts have been directed towards the modification of one or more of these epigenetic mechanisms. In that regard, several cell culture based assays are being used to analyze different epigenetic processes, and small molecule drugs modulate these epigenetic processes. However these tests are not capable of predicting the exact behavior of drug pharmacokinetics and pharmacodynamics in living subjects. The current intense efforts to develop such drugs, as well as an ever increasing interest in epigenetics research, creates a paramount need to develop new more meaningful molecular imaging strategies that can specifically interrogate different epigenetic mechanisms in vivo. The main goal of this proposal is to develop novel in vivo imaging strategies to monitor cellular epigenetic processes in living animals, evaluating these techniques when imaging the basic epigenetic shifts occurring in the development of different cancers, and to apply these imaging platforms to study therapeutic drugs that modulate these processes in cancer. Specifically, we wish to image and quantitate histone methylation in vivo, and to apply this novel analytical tool to evaluate drugs that modulate histone methylation, which may have important applications in molecular therapeutics of cancer. This will be achieved by developing: 1) Optical bioluminescence (Split-Luciferase-complementation), and 2) microPET (Split-Thymidine kinase complementation) imaging sensors. Combinatorial therapies using different epigenetic modulators (inhibitors of histone deacetylases in combination with histone methyltransferases) is curently considered as a new approach for treating cancers and several other intractable cellular diseases. The sensors we are planning to develop by this grant, are having the potential to image molecular events in both cells and in live animals. These sensors will improve the use of epigenetic modulators in translational clinical applications by enabling drug screening and their pre-clinical evaluations in living animals. The aberrant histone methylation has been considered as an important player in the development of cancer. In summary, this proposal will lead to the development of highly sensitive in vivo imaging methods that can be used to further epigenetic research, as well as accelerating the pre-clinical evaluation of drugs targeting different cancers and other cellular diseases. PUBLIC HEALTH RELEVANCE: Currently, abnormal epigenetic mechanisms are regarded as significant contributing factors to the pathophysiology of different diseases, including cancer. Several cell-based assays are being used to identify and analyze drugs that target different epigenetic mechanisms. However most of these tests are not capable of predicting the exact behavior of drug pharmacokinetics and pharmacodynamics in living subjects. The ever- increasing interest in epigenetics research creates an immediate need to develop new more meaningful molecular imaging strategies that can specifically interrogate different epigenetic mechanisms in vivo. The main goal of this proposal is to develop novel in vivo imaging strategies to monitor cellular epigenetic processes in living animals. Specifically, we wish to image and quantitate histone methylation in vivo, and to apply this novel analytical tool to the evaluation of drugs that modulate epigenetic events, which may have important applications in molecular therapeutics of cancer.

描述(申请人提供)：“表观遗传学”是指由潜在DNA序列变化以外的机制引起的表型或基因表达的变化。异常的表观遗传控制机制现在被认为是包括癌症在内的各种疾病的病理生理学的重要贡献因素。在哺乳动物细胞中诱导表型改变的主要表观遗传学机制是DNA甲基化、组蛋白甲基化和组蛋白乙酰化。最近的许多有针对性的药物开发努力都是为了修改这些表观遗传机制中的一个或多个。在这方面，几种基于细胞培养的分析方法正被用于分析不同的表观遗传过程，而小分子药物调节这些表观遗传过程。然而，这些测试不能预测药物在活体受试者中的药代动力学和药效学的确切行为。目前开发此类药物的紧张努力，以及人们对表观遗传学研究日益增长的兴趣，迫切需要开发新的、更有意义的分子成像策略，以具体询问体内不同的表观遗传学机制。这项建议的主要目标是开发新的活体成像策略来监测活动物的细胞表观遗传过程，在成像不同癌症发展过程中发生的基本表观遗传变化时评估这些技术，并应用这些成像平台来研究调节癌症这些过程的治疗药物。具体地说，我们希望对活体中组蛋白甲基化进行成像和定量，并应用这一新的分析工具来评估调节组蛋白甲基化的药物，这可能在癌症的分子治疗中具有重要应用。这将通过开发：1)光学生物发光(分裂-荧光素酶-互补)和2)微型PET(分裂-胸苷激酶互补)成像传感器来实现。使用不同的表观遗传调节剂(组蛋白脱乙酰酶和组蛋白甲基转移酶的抑制剂)的联合治疗目前被认为是治疗癌症和其他几种难治性细胞疾病的一种新方法。我们计划通过这笔拨款开发的传感器，有可能对细胞和活动物中的分子事件进行成像。这些传感器将通过在活体动物中进行药物筛选和临床前评估，改进表观遗传调节剂在转译临床应用中的使用。组蛋白甲基化异常被认为在癌症的发生发展中起重要作用。总而言之，这项提议将导致开发高灵敏度的体内成像方法，可用于进一步的表观遗传学研究，以及加快针对不同癌症和其他细胞疾病的药物的临床前评估。 公共卫生相关性：目前，异常的表观遗传机制被认为是包括癌症在内的不同疾病的病理生理学的重要贡献因素。几种基于细胞的分析方法正被用于识别和分析针对不同表观遗传机制的药物。然而，这些测试中的大多数都不能预测药物在活体中的药代动力学和药效学的确切行为。人们对表观遗传学研究的兴趣与日俱增，迫切需要开发新的、更有意义的分子成像策略，以具体询问体内不同的表观遗传学机制。这项建议的主要目标是开发新的活体成像策略，以监测活动物的细胞表观遗传过程。具体地说，我们希望对体内组蛋白甲基化进行成像和定量，并将这一新的分析工具应用于调节表观遗传事件的药物的评估，这可能在癌症的分子治疗中具有重要应用。